Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954490 | 1.00 | TLR2 (0.57) | TLR2HDAC1HDAC2MDM2MDM4 | |
| SCHEMBL14198731 | 0.97 | TLR2 (0.56) | TLR2HDAC1HDAC2MDM2MDM4 | |
| SCHEMBL29401900 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL30861891 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL29398946 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL3366333 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL120685 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL31186620 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL2589116 | 0.88 | TNF (0.59) | TLR2HDAC1HDAC2MDM4TP53 | |
| SCHEMBL8892538 | 0.88 | MDM2 (0.60) | TLR2HDAC1HDAC2MDM2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| EP-1504094-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | Pharmacia Corporation (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2003095475-A2 | PEPTIDE COMPOUNDS AND THEIR USE AS PROTEASE SUBSTRATES | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018561-A1 | Peptide compounds and their use as protease substrates | MMP3, MMP25, MMP11 | TLR2 4620/4885HDAC1 1031/4885HDAC2 2428/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | TLR2 1355/4885HDAC1 2583/4885HDAC2 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.